Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 23,480	$ 59,640
Short-term investments	335,043	329,462
Accounts receivable, net	1,565	15,678
Inventory	13,016	11,109
Other current assets	7,881	10,063
Total current assets	380,985	425,952
Long-term investments	3,493	0
Property, plant and equipment, net	66,642	65,601
Goodwill	76,501	76,501
Other assets	865	817
Total assets	528,486	568,871
Current liabilities:
Accounts payable	6,951	2,816
Accrued compensation	11,463	18,280
Accrued clinical trial expenses	7,443	7,958
Other accrued expenses	6,576	4,711
Interest payable	4,090	4,198
Capital lease obligations, current portion	2,909	2,908
Liability related to refundable upfront payment	12,500	12,500
Deferred revenue, current portion	24,192	14,352
Other current liabilities	2,391	4,499
Total current liabilities	78,515	72,222
Senior secured notes, net	243,900	243,464
Capital lease obligations, less current portion	1,609	2,223
Liability related to the sale of future royalties, net	103,931	105,950
Deferred revenue, less current portion	51,666	51,887
Other long-term liabilities	4,116	5,000
Total liabilities	483,737	480,746
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at March 31, 2017 or December 31, 2016	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 154,731 shares and 153,212 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	15	15
Capital in excess of par value	2,131,698	2,111,483
Accumulated other comprehensive loss	(1,849)	(2,363)
Accumulated deficit	(2,085,115)	(2,021,010)
Total stockholders’ equity	44,749	88,125
Total liabilities and stockholders’ equity	$ 528,486	$ 568,871